DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Claims 1-15 are pending in the instant application. Claims 10-14 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to non-elected subject matter. The withdrawn subject matter is patentably distinct from the elected subject matter as it differs in structure and element and would require separate search considerations. In addition, a reference which anticipates one group would not render obvious the other. Claims 1, 2, 4-6, 8, 9, and 15 are rejected. Claims 3 and 7 are objected.
Information Disclosure Statement
The information disclosure statement filed on July 24, 2023 has been considered and a signed copy of form 1449 is enclosed herewith.
Election/Restrictions
Applicant’s election without traverse of Group I, claims 1-9 and 15, and the species of BT-H-thiadiazole in the responses filed on July 20, 2026 and February 3, 2026, respectively, are acknowledged. The restriction requirements are still deemed proper and are hereby made final.
The examiner will follow the guidelines of MPEP 803.02 wherein once a species is elected, it is examined for compliance with all applicable statutes for patentability and if compliance is found, then the examination is expanded to a reasonable number of elected species to determine whether they also comply with the statute. The examiner will determine whether the entire scope of the claims is patentable according to MPEP 803.02.
Applicant's elected species appears allowable over the prior art of record. Therefore, according to MPEP 803.02: should no prior art be found that anticipated or renders obvious the elected species, the search of the Markush-type claim will be extended. If prior art is found that anticipated or renders obvious the Markush-type claim with respect to a nonelected species, the Markush-type claim shall be rejected and claims to the nonelected species held withdrawn from further consideration. The search of the Markush-type claim has been extended to the non-elected species wherein:
Acc is
PNG
media_image1.png
98
80
media_image1.png
Greyscale
; and the remaining variables are as defined in the claims.
As prior art has been found which anticipates the above identified nonelected species, the Markush-type claims are rejected as follows and the subject matter of the claims drawn to nonelected species held withdrawn from consideration. Claims 1-9 and 15 have been examined to the extent that they are readable on the elected embodiment and the above identified nonelected species. Since art was found on the nonelected species, subject matter not embraced by the elected embodiment or the above identified nonelected species is therefore withdrawn from further consideration.
Claim Rejections - 35 USC § 102
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claims 1, 2, 4-6, 8, and 9 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Sundar et al. (Phys. Chem. Chem. Phys., 2016, 18, 9133).
Sundar et al. discloses the compounds
PNG
media_image2.png
124
270
media_image2.png
Greyscale
or CH3-D-A-D-CH3 wherein D = thiophene (see right column on page 9139) and A = benzo-thiadiazole (see left column on page 9140) and
PNG
media_image3.png
130
306
media_image3.png
Greyscale
or NH2-D-A-D-NH2 (see Table 2 on page 9139). Therefore, compounds of Formula I wherein Acc is
PNG
media_image1.png
98
80
media_image1.png
Greyscale
wherein R3 and R4 are hydrogen; Don and Don’ are Formula B wherein X is S and R1 and R2 are hydrogen; and Z and Z’ are both -CH3 and both -NH2, respectively, of the claims are anticipated by the reference.
Claims 1, 2, 4-6, 8, 9, and 15 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Thomas et al. (Chem. Eur. J. 2008, 14, 11231-11241).
Thomas et al. discloses the compound
PNG
media_image4.png
244
482
media_image4.png
Greyscale
or compound G1a (i.e., R = tert-Butyl). See page 11232. It is also disclosed that the compound was used in a dichloromethane solution to measure the physical properties of the compound. See Table 1 on page 11234. Therefore, a compound of Formula I wherein Acc is
PNG
media_image1.png
98
80
media_image1.png
Greyscale
wherein R3 and R4 are hydrogen; Don and Don’ are Formula B wherein X is S and R1 and R2 are hydrogen; and Z and Z’ are
PNG
media_image5.png
68
66
media_image5.png
Greyscale
wherein RA is alkyl and a formulation thereof of the claims are anticipated by the reference.
Claim Objections
Claims 3 and 7 are objected for depending on a previous rejected claim. However, even if the claims are amended to be in independent form, they would still not be in condition for allowance because they contain non-elected subject matter (i.e., Acc is not limited to
PNG
media_image1.png
98
80
media_image1.png
Greyscale
). In other words, the subject matter or species which are not embraced by the elected embodiment or the above identified nonelected species have been withdrawn from further consideration.
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to KRISTIN ANN VAJDA whose telephone number is (571)270-5232. The examiner can normally be reached Mon-Fri 6:00-4:00.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James Alstrum-Acevedo can be reached at 571-272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/KRISTIN A VAJDA/Primary Examiner, Art Unit 1622
Prosecution Insights